Gilead Sciences (GILD) PT Lowered to $168 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $156.04 -0.73%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn lowered the price target on Gilead Sciences (NASDAQ: GILD) to $168.00 (from $175.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Gilead Sciences (GILD) PT Raised to $185 at Jefferies
- Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
